Loading
Entera Bio Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Mar 2026.
Entera Bio Ltd.: what insiders have been doing
Entera Bio Ltd. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 20 filings came from 8 insiders.
Every open-market trade in the period is a purchase: 8 purchases worth €120k, from 5 insiders, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Germano Geno J filed the largest purchase, €25k, on 11 February 2026. The buyers include 4 senior executives and 1 chief executive.
Compared with its exchange (5,814 companies, median 19 filings), a count of 20 filings is above the norm. Since 2022, the database holds 31 purchases and no sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 42,000 USD and net income at -11.4 m USD.
In the case of 7 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 11 March 2026, which is 221 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
67
Thresholds
n/a
Buy Volume
€537,100
31 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGeno J. Germano2 buys
Sean Ellis2 buys
Steven D. Rubin2 buys
Haya Taitel1 buy
Miranda Jayne Toledano1 buy
Since the insiders bought
- -11.4%Entry US$1.32 · Close at T+90 US$1.17
- -19.5%Entry US$1.49 · Close at T+90 US$1.20
- -9.3%Entry US$1.40 · Close at T+90 US$1.27
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Entera Bio Ltd. Strong Buy (bullish), based on 4 analysts. Average price target: US$9.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,077 of 24,148 companies
15.0
score / 100
Value28
Quality2
FCF yld-1.6%
Earn yld-2.4%
EV/EBITDA·
ROE-139%
Gross mgn0.0%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.77
Analyst consensus
4 analystsStrong buy
US$9.00Target US$9.75(+252%)US$11.00
Income statement
RevenueUS$42k
EBITDA-US$11.5M-27379% margin
Net income-US$11.4M-27235.7% margin
Valuation
P/Book18.8x
Beta1.41
Balance sheet & cash
Market capUS$481.5M
Total debtUS$490k
Free Cash Flow-US$7.5M
Debt / Equity6%
Profitability & ownership
ROE-138.9%
ROA-46.0%
% insiders5.5%
% institutions34.1%
Last declaration on 7 August 2026
Declarations67 total
20,034 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-003954:0
25,014 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-003949:0
20,790 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-003955:0
22,815 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-003956:0
19,117 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-003957:0
347,567 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-003508:0
72,993 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-003508:1
20,000 shares@ US$1.3047.4% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000825:0
Canonical exit: 7 Jun 2026 (T+90)
10,000 shares@ US$1.239.2% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000787:0
Canonical exit: 3 Jun 2026 (T+90)
5,000 shares@ US$1.4938.2% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000508:0
Canonical exit: 13 May 2026 (T+90)
7,500 shares@ US$1.4827.8% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000414:0
Canonical exit: 11 May 2026 (T+90)
20,000 shares@ US$1.4952.6% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000413:0
Canonical exit: 11 May 2026 (T+90)
10,000 shares@ US$1.2061.8% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000412:0
Canonical exit: 10 May 2026 (T+90)
18,000 shares@ US$1.2416.3% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000411:0
Canonical exit: 10 May 2026 (T+90)
25,371 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000018:0
38,294 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000016:0
28,721 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000020:0
30,157 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000017:0
26,329 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-26-000015:0
11,000 shares@ US$1.810216.5% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-25-004125:0
Canonical exit: 29 Mar 2026 (T+90)
136,842 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-25-002414:0
26,316 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-25-002412:0
26,316 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-25-002410:0
26,316 shares0Ordinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-25-001539:0
23,952 shares@ US$1.0022.0% of flowOrdinary Shares, par value NIS 0.0000769 per shareSEC:0001178913-25-001192:0
25 of 67 declarations
About Entera Bio Ltd.
Entera Bio Ltd. (NASDAQ: ENTX) is a clinical-stage biotechnology company listed in the United States on the NASDAQ market. Although the company is incorporated as an Israeli entity and its operations are largely centered in Israel, it is a U.S.-listed issuer with public reporting under SEC rules. For international investors, Entera fits the profile of a development-stage biotech: limited or no meaningful product revenue today, a valuation driven primarily by clinical execution, regulatory progress, partnership activity, and the company’s ability to fund its pipeline. Entera was incorporated on September 30, 2009 and commenced operations on June 1, 2010.
The company’s core investment thesis is built around an oral delivery platform for peptides and protein replacement therapies. In practical terms, Entera is trying to convert biologic therapies that are typically administered by injection into tablet form. This is a differentiated scientific proposition if it can reliably achieve sufficient bioavailability, safety, and manufacturing consistency. The most advanced assets include EB613, which is being developed for high-risk postmenopausal osteoporosis, and EB612, which targets hypoparathyroidism. Entera is also advancing additional oral peptide programs, including a collaboration with OPKO Health focused on an oral oxyntomodulin / GLP-1 / glucagon candidate for metabolic disease.
Read moreShow less
From a competitive standpoint, Entera operates in a crowded and capital-intensive environment. It competes indirectly with large pharmaceutical companies, specialty endocrinology and metabolism developers, and other peptide-focused biotechs. Its strategic advantage is not scale, but a potentially disruptive formulation platform that could improve patient convenience and adherence if clinical data continue to support the approach. As with most clinical-stage biotech names, the investment case is highly binary: clinical readouts, FDA interactions, intellectual property, partnership structures, and cash runway can materially change the outlook.
Recent corporate developments have been notable. Entera reported full-year 2025 results in March 2026 and first-quarter 2026 results in May 2026. It also announced a direct investment by BVF Partners and expanded its OPKO collaboration, which together help support funding and pipeline progression. Another key update was FDA alignment on a phase 3 study design for EB613, including the use of total hip BMD as the primary endpoint, which may reduce regulatory uncertainty around the program. Overall, Entera Bio remains a speculative but scientifically interesting NASDAQ-listed U.S. biotech name with upside tied to oral peptide development and execution across clinical and financing milestones.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
